An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects With Seizure Clusters

Trial Profile

An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects With Seizure Clusters

Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Midazolam (Primary)
  • Indications Generalised epilepsy; Partial epilepsies
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Upsher-Smith
  • Most Recent Events

    • 19 May 2017 Status changed from recruiting to discontinued.
    • 17 May 2017 This trial has been discontinued in Poland (end date: 22 Feb 2017).
    • 27 Mar 2017 This trial was discontinued in Hungary, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top